Characterizations of HCV NS5A replication complex inhibitors
Donald R. O’Boyle(Bristol-Myers Squibb (United States)), Min Gao(Shandong First Medical University), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), David R. Langley(Bristol-Myers Squibb (United States)), Denis R. St. Laurent(Bristol-Myers Squibb (United States)), Chunfu Wang(People 's Liberation Army 451 Hospital), Peter T. Nower, Robert A. Fridell(Bristol-Myers Squibb (United States)), Jin-Hua Sun(University of Science and Technology of China), J. Romine(Bristol-Myers Squibb (United States)), Michael H. Serrano‐Wu(Broad Institute), Lawrence B. Snyder(Arvinas (United States)), Julie A. Lemm(Bristol-Myers Squibb (United States)), Van N. Nguyen, Makonen Belema
Cited by 49
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Applications of fluorine-containing amino acids for drug design
|European Journal of Medicinal Chemistry|2019|238
Identification of Hepatitis C Virus NS5A Inhibitors
|Journal of Virology|2009|196
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186